Metabolic syndrome and inflammation markers in patients with schizophrenia and recurrent depressive disorder

Psychiatria Danubina

Volumn 26, Issue 3, 2014, Pages 214-219

  Lasić, Davor ^a   Bevanda, Milenko ^b   Bošnjak, Nada ^a   Uglešić, Boran ^a   Glavina, Trpimir ^a   Franić, Tomislav ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b UNIVERSITY OF MOSTAR   (Bosnia and Herzegovina)

Author keywords

CRP; Inflammation markers; Metabolic syndrome; PAI 1; Recurrent depressive disorder; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CORTICOTROPIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID; AUTACOID; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DEPRESSION; ELEVATED BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; RECURRENT DISEASE; SCHIZOPHRENIA; WAIST CIRCUMFERENCE; BLOOD; CASE CONTROL STUDY; COMORBIDITY; CROATIA; CROSS-SECTIONAL STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; REFERENCE VALUE;

ADULT; AGED; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COMORBIDITY; CROATIA; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECURRENCE; REFERENCE VALUES;

EID: 84907172346     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Alexander CM, Landsman PB, Grundy SM: The influence of age and body mass index on the metabolic syndrome and its components. Diabetes Obes Metab 2008; 10:246-50.
2. Dunbar JA, Reddy P, Davis-Lameloise N, Philpot B, Laatikainen T, Kilkkinen A, et al.: Depression: an important comorbidity with metabolic syndrome in a general population. Diabetes Care 2008; 31:2368-73.
3. Ford ES, Giles WH, Mokdad AH: Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27:2444-9.
4. Hoirisch-Clapauch S, Nardi AE, Gris JC, Brenner B: Mental disorders and thrombotic risk. Seminars in Thrombosis and Hemostasis 2013; 39:943-9.
5. Horacek J, Kuzmiakova M, Hoschl C, Andel M, Bahbonh R: The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. Psychoneuroendocrino 1999; 24:785-97.
6. Iacovides A, Siamouli M: Comorbid mental and somatic disorders: an epidemiological perspective. Curr Opin Psychiatr 2008; 21:417-21.
7. Jakovljević M, Crnčević Z, Ljubičić D, Babić D, Topić R, Sarić M: Mental disorders and metabolic syndrome: a fatamorgana or warning reality? Psychiatr Danub 2007; 19:76-86.
8. Jakovljevic M, Reiner Z, Milicic D: Mental disorders, treatment response, mortality and serum cholesterol: a new holistic look at old data. Psychiatr Danub 2007; 19:270-81.
9. Jakovljević M, Ostojić L: Comorbidity and multimorbidity in medicine today: challenges and opportunities for bringing separated branches of medicine closer to each other. Psychiatr Danub 2013; 25(Suppl 1):18-28.
10. John AP, Koloth R, Dragovic M, Lim SC: Prevalence of metabolic syndrome among Australians with severe mental illness. Med J Aust 2009; 190:176-9.
11. Jukić V, Petrović Z, Brečić P, Križaj A, Savić A, Bačeković A, et al.: Psychofarmacology in the prevention of somatic comorbid diseases in mentally ill patients. Psychiatr Danub 2009; 21:350-5.
12. Kinder LS, Carnethon MR, Palaniappan LP, King AC, Fortmann SP: Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med 2004; 66:316-22.
13. Koponen H, Jokelainen J, Keinanen-Kiukaanniemi S, Vanhala M: Depressive symptoms and 10-year risk for cardiovascular morbidity and mortality. World J Biol Psychiatry 2010; 11:834-9.
14. Kozumplik O, Uzun S, Jakovljević M: Psychotic disorders and comorbidity: somatic illness vs. side effect. Psychiatr Danub 2009; 21:361-7.
15. Maes M: Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuro-Psychoph 2011; 35:664-75.
16. Marčinko D, Popović-Knapić V, Franić T, Karlović D, Martinac M, Brataljenović T et al.: Association of cholesterol and socio-demographic parameters with suicidality in the male patients with schizophrenia. Psychiatr Danub 2008; 20:390-5.
17. Maslov B, Jakovljević M, Crnčević Z, Ostojić L, Marčinko D, Babić D, et al.: Metabolic syndrome and schizophrenia from integrative medicine perspective. Psychiatr Danub 2008; 20:384-9.
18. Mueller N: The role of anti-inflammatory treatment in psychiatric disorders. Psychiatr Danub 2013; 25:292-298.
19. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al.: Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86:15-22.
20. Newcomer JW: Metabolic syndrome and mental illness. Am J Manag C 2007; 13(Suppl 1):S170-7.
21. Oreški I, Jakovljević M, Aukst-Margetić B, Orlić ZC, Vuksan-Ćusa B: Comorbidity and multimorbidity in patients with schizophrenia and bipolar disorder: similarities and differencies. Psychiatr Danub 2012; 24:80-5.
22. Polašek O: Future of biobanks - bigger, longer, and more dimensional. Croat Med J 2013; 54:496-500.
23. Topić R, Miličić D, Štimac Z, Lončar M, Velagić V, Marčinko D, et al.: Somatic comorbidity, metabolic syndrome, cardiovascular risk, and CRP in patients with recurrent depressive disorders. Croat Med J 2013; 54:453-9.
24. Silić A, Karlović D, Serretti A: Increased inflammation and lower platelet 5-HT in depression with metabolic syndrome. J Affect Disorders 2012; 141:72-8.
25. Vancampfort D, Correll CU, Wampers M, Sienaert P, Mitchell AJ, De Hert M et al.: Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychol Med 2013: 21:1-12.
26. Vuksan-Ćusa B, Šagud M, Jakovljević M: C-reactive protein and metabolic syndrome in patients with bipolar disorder compared to patients with schizophrenia. Psychiatr Danub 2010; 22:275-7.
27. Vuksan-Ćusa B, Šagud M, Jakovljević M, Peles A, Jaksic N, Mihaljevic S et al.: Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia. Nord J Psychiatry 2013: 67:320-325.
28. Vuksan-Ćusa B, Šagud M, Mihaljević A, Jakšić N, Jakovljević M: Metabolic syndrome and cortisol/DHEAS ratio in patients with bipolar disorder and schizophrenia. Psychiatr Danub 2014; 26:187-189.
29. Young JJ, Bruno D, Pomara N: A review of the relationship between proinflammatory cytokines and major depressive disorder. J Affect Disord 2014; 169-15-20.